Clinical-stage biotechnology company developing regenerative medicine and cell therapies, primarily for ophthalmology
Clinical-stage biotechnology company developing regenerative medicine and cell therapies, primarily for ophthalmology. Its pluripotent stem cell platforms included human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), with clinical programs for Stargardt disease and age-related and myopic macular degeneration. Ocata was acquired by Astellas Pharma in 2016.